Perceptive Advisors

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.

Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.

Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.

Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, focused on developing and commercializing approved and late-stage cancer therapies. The company aims to improve treatment outcomes and reduce healthcare costs by providing a range of cancer treatments, from primary therapies to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells, enhancing patients' immune responses during cancer treatment. Formerly known as Partners Oncology, Inc., the company rebranded in November 2017. Partner Therapeutics serves as a vital link between researchers and healthcare professionals, facilitating the advancement of cancer therapies.

Xontogeny LLC, founded in 2016 and based in Boston, Massachusetts, is a life sciences accelerator that focuses on the development of pharmaceuticals and related technologies. The company aims to enhance the success rates of early-stage drug and technology ventures by providing strategic guidance, operational support, and leadership to entrepreneurs. By partnering closely with founding scientists and innovators, Xontogeny promotes a more efficient development model that aligns with the vision of its partners while benefiting company founders and early equity holders. The firm primarily invests in the healthcare and life science sectors, striving to accelerate the advancement of life science technologies.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.